Analysts Set enGene Holdings Inc. (NASDAQ:ENGN) Price Target at $33.67

enGene Holdings Inc. (NASDAQ:ENGN) has earned a consensus recommendation of “Buy” from the seven analysts that are covering the firm, Marketbeat.com reports. Seven investment analysts have rated the stock with a buy recommendation. The average twelve-month price target among analysts that have issued ratings on the stock in the last year is $33.67.

A number of research firms have recently issued reports on ENGN. Morgan Stanley reissued an “overweight” rating and set a $40.00 price objective on shares of enGene in a research report on Wednesday, September 11th. Oppenheimer reiterated an “outperform” rating and issued a $30.00 price target on shares of enGene in a report on Tuesday, September 24th.

enGene Price Performance

Shares of ENGN opened at $8.12 on Monday. enGene has a 52-week low of $4.42 and a 52-week high of $18.40. The company has a debt-to-equity ratio of 0.09, a current ratio of 19.52 and a quick ratio of 19.52. The business’s 50 day moving average price is $7.58 and its two-hundred day moving average price is $8.88.

enGene (NASDAQ:ENGN) last released its earnings results on Tuesday, September 10th. The company reported ($0.32) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.37) by $0.05. Research analysts forecast that enGene will post -1.54 EPS for the current year.

Insider Buying and Selling at enGene

In related news, major shareholder Growth Opportunities F. Forbion acquired 11,844 shares of the stock in a transaction dated Monday, October 7th. The stock was purchased at an average cost of $6.55 per share, with a total value of $77,578.20. Following the completion of the purchase, the insider now directly owns 2,469,833 shares in the company, valued at $16,177,406.15. This trade represents a 0.00 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other news, major shareholder Growth Opportunities F. Forbion bought 11,844 shares of enGene stock in a transaction dated Monday, October 7th. The stock was purchased at an average price of $6.55 per share, for a total transaction of $77,578.20. Following the purchase, the insider now directly owns 2,469,833 shares in the company, valued at $16,177,406.15. The trade was a 0.00 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, major shareholder Growth Opportunities F. Forbion bought 5,997 shares of the stock in a transaction dated Friday, October 4th. The stock was purchased at an average price of $6.54 per share, with a total value of $39,220.38. Following the acquisition, the insider now owns 2,457,989 shares of the company’s stock, valued at $16,075,248.06. The trade was a 0.00 % increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last quarter, insiders purchased 420,965 shares of company stock worth $2,651,103. Insiders own 13.70% of the company’s stock.

Hedge Funds Weigh In On enGene

Hedge funds and other institutional investors have recently modified their holdings of the business. Wolverine Asset Management LLC purchased a new stake in shares of enGene during the third quarter valued at approximately $37,000. Altitude Crest Partners Inc. bought a new position in enGene in the 1st quarter valued at $2,039,000. SR One Capital Management LP bought a new position in enGene in the 2nd quarter valued at $4,715,000. Logos Global Management LP increased its position in shares of enGene by 50.0% during the 2nd quarter. Logos Global Management LP now owns 1,200,000 shares of the company’s stock valued at $11,316,000 after purchasing an additional 400,000 shares during the last quarter. Finally, Janus Henderson Group PLC bought a new stake in shares of enGene during the 1st quarter worth $17,095,000. Hedge funds and other institutional investors own 64.16% of the company’s stock.

About enGene

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.